A covalently bound inhibitor triggers EZH2 degradation through CHIP‐mediated ubiquitination

Enhancer of zeste homolog 2 (EZH2) has been characterized as a critical oncogene and a promising drug target in human malignant tumors. The current EZH2 inhibitors strongly suppress the enhanced enzymatic function of mutant EZH2 in some lymphomas. However, the recent identification of a PRC2‐ and me...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xu, Cao, Wei, Zhang, Jianjun, Yan, Ming, Xu, Qin, Wu, Xiangbing, Wan, Lixin, Zhang, Zhiyuan, Zhang, Chenping, Qin, Xing, Xiao, Meng, Ye, Dongxia, Liu, Yuyang, Han, Zeguang, Wang, Shaomeng, Mao, Li, Wei, Wenyi, Chen, Wantao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412902/
https://www.ncbi.nlm.nih.gov/pubmed/28320739
http://dx.doi.org/10.15252/embj.201694058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412902/
https://www.ncbi.nlm.nih.gov/pubmed/28320739
http://dx.doi.org/10.15252/embj.201694058

Ejemplares similares